Allarity Therapeutics announced that its wholly-owned subsidiary, Allarity Sponsor LLC, formed a new special purpose acquisition company (SPAC), Allarity Acquisition Corp., which filed a Form S-1 registration statement for a proposed initial public offering. The base offering size is $100 million, potentially increasing to $115 million with full underwriter over-allotment exercise. Following the separation, the SPAC's Class A ordinary shares and warrants are expected to trade on Nasdaq under symbols "ALLN" and "ALLNW," while Allarity Sponsor LLC will hold approximately 25% of the SPAC post-offering. Jesper Hoiland, a current Allarity board member and former Novo Nordisk executive, will serve as Chairman of the SPAC's board. This strategic capital allocation does not alter Allarity’s existing working capital runway extending into summer 2028. Allarity Therapeutics is a clinical-stage biopharmaceutical company developing stenoparib, a dual PARP/Wnt pathway inhibitor for cancer treatment.

Allarity Therapeutics reported financial results for the second quarter ended June 30, 2026, ending with $26.9 million in cash and restricted cash. The company completed a Phase 3-ready manufacturing campaign for its drug candidate stenoparib in July 2026 and obtained CLIA certification for its in-house laboratory to support clinical trials. Additionally, the USPTO granted a key U.S. patent protecting the exclusivity of stenoparib when used with its DRP companion diagnostic into April 2042. R&D expenses were $1.3 million and G&A expenses were $1.3 million for the quarter. Allarity Therapeutics is a clinical-stage biopharmaceutical company developing personalized cancer treatments using stenoparib and its proprietary drug response predictor technology.

Allarity Therapeutics, Inc. held its annual meeting on June 26, 2026, where stockholders approved the election of Jesper Hoiland, the ratification of Wolf & Company, P.C. as independent auditors, an increase in the 2021 Equity Incentive Plan share authorization to 2,021,990, advisory executive compensation, and the issuance of shares to Tumim Stone Capital LLC in excess of the Exchange Cap. A proposal to limit officer liability via an amendment to the Certificate of Incorporation failed to pass. Additionally, the company announced on June 30, 2026, that the USPTO granted a U.S. patent for its stenoparib-specific Drug Response Predictor (DRP®) companion diagnostic. Allarity Therapeutics is a biotechnology company developing precision medicines.

Allarity Therapeutics announced the presentation of a Trial-in-Progress poster at the ESMO Gynaecological Cancers Congress 2026, held June 17–19, 2026, in Copenhagen, Denmark. The company operates in the biotechnology industry and develops therapeutic treatments for cancer.